It will be available in the US in 150 mg and 420 mg doses and at a 10% discount on the wholesale cost of the reference product. Actual costs to patients and providers are expected to be even lower.

Brendan O’Grady, Executive Vice President of North America Commercial at Teva, said the company was proud to make the product available to patients in the US. ‘The launch of Herzuma continues our commitment to help lower healthcare costs and increase price competition through the availability of biosimilars’.

Mr Hyoung-Ki Kim, Vice Chairman at Celltrion, added: ‘We look forward to continuing our partnership with Teva to bring biosimilars to as many patients as possible in the US, as we believe they address an unmet need in the market’.

All in all, it is a successful period for Celltrion, who reported annual sales in excess of ₩1 trillion in 2019 (equivalent to around US$835 million). This is an increase of almost 15% on 2018’s figures.

‘Despite a rise in costs in the process of securing growth engines, such as the introduction of outsourcing contract manufacturing organization (CMO) and the production of biosimilar clinical materials, the operating profit margin is maintaining at a stable level’, Celltrion said in a statement.

Related articles
Celltrion to build facility in China and increase new drug output

Celltrion and Juno make biosimilars deal in Australia and Herzuma launches in Iraq

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Trastuzumab biosimilar Herzuma approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Mar 27]. Available from: www.gabionline.net/Biosimilars/News/Trastuzumab-biosimilar-Herzuma-approved-in-Canada

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.